Eng-King Tan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8606851/publications.pdf

Version: 2024-02-01

119 papers	3,868 citations	117625 34 h-index	149698 56 g-index
119 all docs	119 docs citations	119 times ranked	4952 citing authors

#	Article	IF	Citations
1	Neurodegenerative diseases associated with non-coding CGG tandem repeat expansions. Nature Reviews Neurology, 2022, 18, 145-157.	10.1	17
2	The association between Parkinsonâ€™s disease and Sexual dysfunction: Clinical correlation and therapeutic implications. Ageing Research Reviews, 2022, 79, 101665.	10.9	7
3	Movement disorders in 2020: clinical trials, genetic discoveries, and COVID-19. Lancet Neurology, The, 2021, 20, 10-12.	10.2	3
4	Adapting to post-COVID19 research in Parkinson's disease: Lessons from a multinational experience. Parkinsonism and Related Disorders, 2021, 82, 146-149.	2.2	7
5	Remote Prescription During Pandemic: Challenges and Solutions. Archives of Medical Research, 2021, 52, 450-452.	3.3	6
6	Quality of life in isolated dystonia: non-motor manifestations matter. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 622-628.	1.9	27
7	â€œHot cross bunâ€•is a potential imaging marker for the severity of cerebellar ataxia in MSA-C. Npj Parkinson's Disease, 2021, 7, 15.	5.3	20
8	Association study of MCCC1/LAMP3 and DGKQ variants with Parkinsonâ€™s disease in patients of Malay ancestry. Neurological Sciences, 2021, 42, 4203-4207.	1.9	5
9	The role of gut dysbiosis in Parkinsonâ€™s disease: mechanistic insights and therapeutic options. Brain, 2021, 144, 2571-2593.	7.6	119
10	Transâ€Ethnic Fineâ€Mapping of the Major Histocompatibility Complex Region Linked to Parkinson's Disease. Movement Disorders, 2021, 36, 1805-1814.	3.9	14
11	Case-control study of hypertension and Parkinsonâ€™s disease. Npj Parkinson's Disease, 2021, 7, 63.	5.3	8
12	Functional Neurological Disorders and <scp>COVIDâ€19</scp> Vaccination. Annals of Neurology, 2021, 90, 328-328.	5.3	6
13	Genetic Studies of Parkinson's and Alzheimer's Disease in Latinos/Hispanics: New Insights and Challenges. Annals of Neurology, 2021, 90, 350-352.	5.3	0
14	Lewy Bodyâ€“like Inclusions in Human Midbrain Organoids Carrying Glucocerebrosidase and Î±â€Synuclein Mutations. Annals of Neurology, 2021, 90, 490-505.	5.3	43
15	Fist-Edge-Palm (FEP) test has a high sensitivity in differentiating dementia from normal cognition in Parkinson's disease. Journal of the Neurological Sciences, 2021, 429, 118060.	0.6	0
16	Applying Artificial Intelligence to Multiâ€Omic Data: New Functional Variants in Parkinson's Disease. Movement Disorders, 2021, 36, 347-347.	3.9	5
17	Essential tremor. Nature Reviews Disease Primers, 2021, 7, 83.	30.5	56
18	Essential tremor-plus: a controversial new concept. Lancet Neurology, The, 2020, 19, 266-270.	10.2	82

#	Article	IF	Citations
19	Neurological research & training after the easing of lockdown in countries impacted by COVID-19. Journal of the Neurological Sciences, 2020, 418, 117105.	0.6	3
20	Messaging Fatigue and Desensitisation to Information During Pandemic. Archives of Medical Research, 2020, 51, 716-717.	3.3	40
21	Olfactory dysfunction and COVID-19. Lancet Psychiatry,the, 2020, 7, 663.	7.4	7
22	Safeguarding Non-COVID-19 Research: Looking Up from Ground Zero. Archives of Medical Research, 2020, 51, 731-732.	3.3	7
23	Association of NOTCH2NLC Repeat Expansions With Parkinson Disease. JAMA Neurology, 2020, 77, 1559.	9.0	66
24	Coâ€•occurring mutations of optineurin (OPTN) and colonyâ€•stimulating factorâ€•1 receptor (CSF1R) genes in a family with familial frontotemporal dementia. Alzheimer's and Dementia, 2020, 16, e037542.	0.8	0
25	High Outpatient Attendance During <scp>COVID</scp>â€•19 Lockdown When Patients Were Given the Option to Return. Movement Disorders, 2020, 35, 2137-2138.	3.9	2
26	New Insights into Immune-Mediated Mechanisms in Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 9302.	4.1	16
27	Mental health of scientists in the time of COVID-19. Brain, Behavior, and Immunity, 2020, 88, 956.	4.1	14
28	<scp>NOTCH2NLC GGC</scp> Repeat Expansions Are Associated with Sporadic Essential Tremor: Variable Disease Expressivity on Longâ€•term Followâ€•up. Annals of Neurology, 2020, 88, 614-618.	5.3	36
29	Phenotypic bases of <scp>NOTCH2NLC GGC</scp> expansion positive neuronal intranuclear inclusion disease in a Southeast Asian cohort. Clinical Genetics, 2020, 98, 274-281.	2.0	25
30	Parkinson disease and the immune system â€” associations, mechanisms and therapeutics. Nature Reviews Neurology, 2020, 16, 303-318.	10.1	254
31	Identification of Risk Loci for Parkinson Disease in Asians and Comparison of Risk Between Asians and Europeans. JAMA Neurology, 2020, 77, 746.	9.0	170
32	Parkinsonâ€™s disease following COVID-19: causal link or chance occurrence?. Journal of Translational Medicine, 2020, 18, 493.	4.4	9
33	Chetomin rescues pathogenic phenotype of LRRK2 mutation in drosophila. Aging, 2020, 12, 18561-18570.	3.1	4
34	LRRK2 N551K and R1398H variants are protective in Malays and Chinese in Malaysia: A caseâ€“control association study for Parkinson's disease. Molecular Genetics & Genomic Medicine, 2019, 7, e604.	1.2	11
35	Parkinson's disease in the Western Pacific Region. Lancet Neurology, The, 2019, 18, 865-879.	10.2	116
36	Periventricular White Matter Abnormalities on Diffusion Tensor Imaging of Postural Instability Gait Disorder Parkinsonism. American Journal of Neuroradiology, 2019, 40, 609-613.	2.4	7

#	Article	IF	Citations
37	Towards better cellular replacement therapies in Parkinson disease. Journal of Neuroscience Research, 2018, 96, 219-221.	2.9	1
38	Genome-wide association study of Parkinsonâ€™s disease in East Asians. Human Molecular Genetics, 2017, 26, ddw379.	2.9	94
39	Higher Peripheral TREM2 mRNA Levels Relate to Cognitive Deficits and Hippocampal Atrophy in Alzheimerâ€™s Disease and Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2017, 58, 413-423.	2.6	38
40	Targeting LRRK2 in Parkinsonâ€™s disease: an update on recent developments. Expert Opinion on Therapeutic Targets, 2017, 21, 601-610.	3.4	39
41	O2-06-06: Higher Peripheral Trem2 Mrna Expression Levels are Related to Cognitive Deficits and Hippocampal Atrophy in Alzheimer's Disease and Amnestic MCI. , 2016, 12, P241-P241.		0
42	Antioxidants inhibit neuronal toxicity in Parkinson's diseaseâ€linked LRRK 2. Annals of Clinical and Translational Neurology, 2016, 3, 288-294.	3.7	36
43	FUS-linked essential tremor associated with motor dysfunction in Drosophila. Human Genetics, 2016, 135, 1223-1232.	3.8	9
44	Chromosomal deletion at 22q11.2 and Parkinson's disease. Lancet Neurology, The, 2016, 15, 538-540.	10.2	4
45	Linking a genomeâ€wide association study signal to a LRRK2 coding variant in Parkinson's disease. Movement Disorders, 2016, 31, 484-487.	3.9	8
46	Genetics of essential tremor. Parkinsonism and Related Disorders, 2016, 22, S176-S178.	2.2	46
47	Patterns of linkage disequilibrium at PARK16 may explain variances in genetic association studies. Movement Disorders, 2015, 30, 1335-1342.	3.9	8
48	Mitochondrial serine protease HTRA2 gene mutation in Asians with coexistent essential tremor and Parkinson disease. Neurogenetics, 2015, 16, 241-242.	1.4	14
49	F-box protein 7 mutations promote protein aggregation in mitochondria and inhibit mitophagy. Human Molecular Genetics, 2015, 24, 6314-6330.	2.9	64
50	Sexual dysfunction is associated with postural instability gait difficulty subtype of Parkinsonâ€™s disease. Journal of Neurology, 2015, 262, 2433-2439.	3.6	13
51	In vivo evidence of pathogenicity of VPS35 mutations in the Drosophila. Molecular Brain, 2014, 7, 73.	2.6	35
52	Genetic testing of LRRK2 in Parkinson's disease: is there a clinical role?. Parkinsonism and Related Disorders, 2014, 20, S54-S56.	2.2	8
53	Transcallosal diffusion tensor abnormalities in predominant gait disorder parkinsonism. Parkinsonism and Related Disorders, 2014, 20, 53-59.	2.2	46
54	Targeting leucine-rich repeat kinase 2 in Parkinson's disease. Expert Opinion on Therapeutic Targets, 2013, 17, 1471-1482.	3.4	14

#	Article	IF	Citations
55	Next-generation sequencing diagnostics for neurological diseases/disorders: from a clinical perspective. Human Genetics, 2013, 132, 721-734.	3.8	12
56	Utility of next-generation sequencing in ataxias. Nature Reviews Neurology, 2013, 9, 614-615.	10.1	1
57	Differentiating Non-Motor Symptoms in Parkinson's Disease from Controls and Hemifacial Spasm. PLoS ONE, 2013, 8, e49596.	2.5	9
58	Whole-genome and whole-exome sequencing in neurological diseases. Nature Reviews Neurology, 2012, 8, 508-517.	10.1	99
59	Sleep and Parkinson's disease: A review of caseâ€control polysomnography studies. Movement Disorders, 2012, 27, 1729-1737.	3.9	84
60	Clinical evidence linking coffee and tea intake with Parkinsonâ€™s disease. Basal Ganglia, 2011, 1, 127-130.	0.3	8
61	Case Control Polysomnographic Studies of Sleep Disorders in Parkinson's Disease. PLoS ONE, 2011, 6, e22511.	2.5	121
62	Rare and common LRRK2 exonic variants in Parkinson's disease. Lancet Neurology, The, 2011, 10, 869-870.	10.2	5
63	Lingo2 variants associated with essential tremor and Parkinsonâ€™s disease. Human Genetics, 2011, 129, 611-615.	3.8	50
64	Association of GWAS loci with PD in China. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 334-339.	1.7	58
65	Mutations inLRRK2increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death. Human Mutation, 2011, 32, 1390-1397.	2.5	111
66	Ring finger protein 146/Iduna is a Poly(ADP-ribose) polymer binding and PARsylation dependent E3 ubiquitin ligase. Cell Adhesion and Migration, 2011, 5, 463-471.	2.7	41
67	Notch as a molecular switch in neural stem cells. IUBMB Life, 2010, 62, 618-623.	3.4	63
68	Notch as a molecular switch in neural stem cells. IUBMB Life, 2010, 62, spcone-spcone.	3.4	3
69	Linking LINGO1 to essential tremor. European Journal of Human Genetics, 2010, 18, 739-740.	2.8	13
70	Development of Parkinsonâ€™s disease biomarkers. Expert Review of Neurotherapeutics, 2010, 10, 1811-1825.	2.8	9
71	Clinically reported heterozygous mutations in the PINK1 kinase domain exert a gene dosage effect. Human Mutation, 2009, 30, 1551-1557.	2.5	12
72	Non-synonymous GIGYF2 variants in Parkinsonâ€™s disease from two Asian populations. Human Genetics, 2009, 126, 425-430.	3.8	17

#	Article	IF	Citations
73	Molecular biology changes associated with LRRK2 mutations in Parkinson's disease. Journal of Neuroscience Research, 2008, 86, 1895-1901.	2.9	28
74	Testâ€“retest repeatability of assessing environmental and lifestyle factors in Parkinson's disease. Movement Disorders, 2008, 23, 1032-1036.	3.9	5
75	Pathogenicity of LRRK2 P755L variant in Parkinson's disease. Movement Disorders, 2008, 23, 734-736.	3.9	12
76	Evidence of increased odds of essential tremor in Parkinson's disease. Movement Disorders, 2008, 23, 993-997.	3.9	81
77	Case control MRâ€CISS and 3D TOF MRA imaging study of medullary compression and hypertension in hemifacial spasm. Movement Disorders, 2008, 23, 1820-1824.	3.9	12
78	Spectrum of anxiety symptoms in hyperkinesias. Movement Disorders, 2008, 23, 1795-1795.	3.9	8
79	Essential tremor and the common LRRK2 G2385R variant. Parkinsonism and Related Disorders, 2008, 14, 569-571.	2.2	15
80	Growth rate of patient-derived lymphoblastoid cells with LRRK2 mutations. Molecular Genetics and Metabolism, 2008, 95, 113.	1.1	5
81	Treatment outcome correlates with knowledge of disease in hemifacial spasm. Clinical Neurology and Neurosurgery, 2008, 110, 813-817.	1.4	14
82	Neurovascular compression syndromes and hypertension: clinical relevance. Nature Clinical Practice Neurology, 2007, 3, 416-417.	2.5	5
83	Association between caffeine intake and risk of Parkinson's disease among fast and slow metabolizers. Pharmacogenetics and Genomics, 2007, 17, 1001-1005.	1.5	46
84	Isolated facial myorhythmia. Journal of the Neurological Sciences, 2007, 252, 36-38.	0.6	11
85	Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population. Journal of the Neurological Sciences, 2007, 252, 113-120.	0.6	40
86	Genetic analysis of SCA 27 in ataxia and childhood onset postural tremor. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 395-396.	1.7	1
87	Pathogenic mutations in Parkinson disease. Human Mutation, 2007, 28, 641-653.	2.5	212
88	Valproate-induced Parkinsonism in epilepsy patients. Movement Disorders, 2007, 22, 130-133.	3.9	72
89	LRRK2 G2019S founder haplotype in the Chinese population. Movement Disorders, 2007, 22, 105-107.	3.9	10
90	Impaired motor imagery in patients with essential tremor: A case control study. Movement Disorders, 2007, 22, 504-508.	3.9	6

#	Article	IF	Citations
91	Comparing LRRK2 Gly2385Arg carriers with noncarriers. Movement Disorders, 2007, 22, 749-750.	3.9	19
92	Analysis of LRRK2 Gly2385Arg genetic variant in nonâ€Chinese Asians. Movement Disorders, 2007, 22, 1816-1818.	3.9	33
93	Genetic analysis of SCA 2 and 3 repeat expansions in essential tremor and atypical Parkinsonism. Movement Disorders, 2007, 22, 1971-1974.	3.9	20
94	Acute ataxia, Graves' disease, and stiff person syndrome. Movement Disorders, 2007, 22, 1969-1971.	3.9	13
95	Polymorphisms in candidate genes: implications for the current treatment of Parkinsonâ€™s disease. Expert Opinion on Pharmacotherapy, 2006, 7, 849-855.	1.8	9
96	Restless Legs Syndrome and Parkinsonâ€™s Disease: Is there an etiologic link?. Journal of Neurology, 2006, 253, vii33-vii37.	3.6	20
97	PINK1 mutations in sporadic early-onset Parkinson's disease. Movement Disorders, 2006, 21, 789-793.	3.9	88
98	Movement disorders associated with hyperthyroidism: Expanding the phenotype. Movement Disorders, 2006, 21, 1054-1055.	3.9	18
99	Caseâ€“control study of UCHL1 S18Y variant in Parkinson's disease. Movement Disorders, 2006, 21, 1765-1768.	3.9	26
100	Caseâ€“control study of anxiety symptoms in hemifacial spasm. Movement Disorders, 2006, 21, 2145-2149.	3.9	25
101	Identification of a common genetic risk variant (LRRK2 Gly2385Arg) in Parkinson's disease. Annals of the Academy of Medicine, Singapore, 2006, 35, 840-2.	0.4	18
102	Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 137B, 1-4.	1.7	23
103	Sensory tricks and treatment in primary lingual dystonia. Movement Disorders, 2005, 20, 388-388.	3.9	20
104	Alpha-synuclein mRNA expression in sporadic Parkinson's disease. Movement Disorders, 2005, 20, 620-623.	3.9	48
105	Effect of MDR1 Haplotype on Risk of Parkinson Disease. Archives of Neurology, 2005, 62, 460.	4.5	66
106	Behind the facial twitch: depressive symptoms in hemifacial spasm. Parkinsonism and Related Disorders, 2005, 11, 241-245.	2.2	46
107	An urge to move withL-thyroxine: Clinical, biochemical, and polysomnographic correlation. Movement Disorders, 2004, 19, 1365-1367.	3.9	27
108	Nurr1 mutational screen in Parkinson's disease. Movement Disorders, 2004, 19, 1503-1505.	3.9	18

#	Article	IF	Citations
109	Severe bruxism following basal ganglia infarcts: insights into pathophysiology. Journal of the Neurological Sciences, 2004, 217, 229-232.	0.6	29
110	Botulinum toxin improves quality of life in hemifacial spasm: validation of a questionnaire (HFS-30). Journal of the Neurological Sciences, 2004, 219, 151-155.	0.6	75
111	Genetic analysis of DJ-1 in a cohort Parkinsonâ€™s disease patients of different ethnicity. Neuroscience Letters, 2004, 367, 109-112.	2.1	24
112	Analysis of MDR1 haplotypes in Parkinson's disease in a white population. Neuroscience Letters, 2004, 372, 240-244.	2.1	44
113	Psychogenic tics: diagnostic value of the placebo test. Journal of Child Neurology, 2004, 19, 976-7.	1.4	7
114	Dopamine D2 receptor TaqIA and TaqIB polymorphisms in Parkinson's disease. Movement Disorders, 2003, 18, 593-595.	3.9	27
115	Vascular parkinsonism in moyamoya: Microvascular biopsy and imaging correlates. Annals of Neurology, 2003, 54, 836-840.	5.3	12
116	Alpha synuclein promoter and risk of Parkinson's disease: microsatellite and allelic size variability. Neuroscience Letters, 2003, 336, 70-72.	2.1	61
117	Genetic analysis of Nurr1 haplotypes in Parkinson's disease. Neuroscience Letters, 2003, 347, 139-142.	2.1	30
118	Dopamine agonists and their role in Parkinsonâ€™s disease treatment. Expert Review of Neurotherapeutics, 2003, 3, 805-810.	2.8	5
119	â€œMyorhythmiaâ€•slow facial tremor from chronic interferon alpha-2a usage. Neurology, 2003, 61, 1302-1303.	1.1	29